Estrogen Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer and Stage IV Breast Cancer Clinical Trial Using tamoxifen citrate, polymerase chain reaction, pharmacological study, gene expression analysis, immunohistochemistry staining method, pharmacogenomic studies, matrix-assisted laser desorption/ionization time of flight mass spectrometry, polymorphism analysis, therapeutic conventional surgery, nucleic acid sequencing and protein analysis

- The folks at Roswell Park Cancer Institute are studying the effects of tamoxifen citrate; polymerase chain reaction; pharmacological study; gene expression analysis; immunohistochemistry staining method; pharmacogenomic studies; matrix-assisted laser desorption/ionization time of flight mass spectrometry; polymorphism analysis; therapeutic conventional surgery; nucleic acid sequencing; protein analysis on Estrogen Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer and Stage IV Breast Cancer in females ages 18 years and older. This clinical trial is slated to start December 2007.

Overall Study Contact Info
StatusName Contact Phone
Recruiting

This study is officially titled, "Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients."

Locations

University of Chicago

Chicago, Illinois - Recruiting

Roswell Park Cancer Institute

Buffalo, New York - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.